Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
- Sponsor
- Changhua Christian Hospital
- Study ID
- NCT03793400
- Status
- Completed
Conditions
- Choroidal Neovascularization
- Punctate Inner Choroidopathy
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab Injection — DRUGAnti-vascular endothelial growth factor (VEGF)
Study Details
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.
Key Dates
- First listed
- Jan 4, 2019
- Start date
- Mar 13, 2018
- Status verified
- Jan 2019
- Primary completion
- Apr 13, 2018
- Completion
- Dec 28, 2018
Study Design
- Enrollment
- 22 participants (actual)
Primary Outcome Measure
Wilcoxon Signed-Rank test [ Time Frame: Baseline,48 month. ]
Related Studies
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Scottsdale, Arizona
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)PHASE2/PHASE3 · Recruiting · EyeBiotech Ltd. · Gilbert, Arizona